• Something wrong with this record ?

An automated workflow based on data independent acquisition for practical and high-throughput personalized assay development and minimal residual disease monitoring in multiple myeloma patients

C. Wijnands, G. Armony, S. Noori, J. Gloerich, V. Bonifay, H. Caillon, TM. Luider, S. Brehmer, L. Pfennig, T. Srikumar, D. Trede, G. Kruppa, T. Dejoie, MM. van Duijn, AJ. van Gool, JFM. Jacobs, HJCT. Wessels

. 2024 ; 62 (12) : 2507-2518. [pub] 20240617

Language English Country Germany

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc25003392

OBJECTIVES: Minimal residual disease (MRD) status in multiple myeloma (MM) is an important prognostic biomarker. Personalized blood-based targeted mass spectrometry detecting M-proteins (MS-MRD) was shown to provide a sensitive and minimally invasive alternative to MRD-assessment in bone marrow. However, MS-MRD still comprises of manual steps that hamper upscaling of MS-MRD testing. Here, we introduce a proof-of-concept for a novel workflow using data independent acquisition-parallel accumulation and serial fragmentation (dia-PASEF) and automated data processing. METHODS: Using automated data processing of dia-PASEF measurements, we developed a workflow that identified unique targets from MM patient sera and personalized protein sequence databases. We generated patient-specific libraries linked to dia-PASEF methods and subsequently quantitated and reported M-protein concentrations in MM patient follow-up samples. Assay performance of parallel reaction monitoring (prm)-PASEF and dia-PASEF workflows were compared and we tested mixing patient intake sera for multiplexed target selection. RESULTS: No significant differences were observed in lowest detectable concentration, linearity, and slope coefficient when comparing prm-PASEF and dia-PASEF measurements of serial dilutions of patient sera. To improve assay development times, we tested multiplexing patient intake sera for target selection which resulted in the selection of identical clonotypic peptides for both simplex and multiplex dia-PASEF. Furthermore, assay development times improved up to 25× when measuring multiplexed samples for peptide selection compared to simplex. CONCLUSIONS: Dia-PASEF technology combined with automated data processing and multiplexed target selection facilitated the development of a faster MS-MRD workflow which benefits upscaling and is an important step towards the clinical implementation of MS-MRD.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003392
003      
CZ-PrNML
005      
20250206104321.0
007      
ta
008      
250121s2024 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1515/cclm-2024-0306 $2 doi
035    __
$a (PubMed)38872409
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Wijnands, Charissa $u Laboratory of Medical Immunology, Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, The Netherlands $1 https://orcid.org/0000000190578751
245    13
$a An automated workflow based on data independent acquisition for practical and high-throughput personalized assay development and minimal residual disease monitoring in multiple myeloma patients / $c C. Wijnands, G. Armony, S. Noori, J. Gloerich, V. Bonifay, H. Caillon, TM. Luider, S. Brehmer, L. Pfennig, T. Srikumar, D. Trede, G. Kruppa, T. Dejoie, MM. van Duijn, AJ. van Gool, JFM. Jacobs, HJCT. Wessels
520    9_
$a OBJECTIVES: Minimal residual disease (MRD) status in multiple myeloma (MM) is an important prognostic biomarker. Personalized blood-based targeted mass spectrometry detecting M-proteins (MS-MRD) was shown to provide a sensitive and minimally invasive alternative to MRD-assessment in bone marrow. However, MS-MRD still comprises of manual steps that hamper upscaling of MS-MRD testing. Here, we introduce a proof-of-concept for a novel workflow using data independent acquisition-parallel accumulation and serial fragmentation (dia-PASEF) and automated data processing. METHODS: Using automated data processing of dia-PASEF measurements, we developed a workflow that identified unique targets from MM patient sera and personalized protein sequence databases. We generated patient-specific libraries linked to dia-PASEF methods and subsequently quantitated and reported M-protein concentrations in MM patient follow-up samples. Assay performance of parallel reaction monitoring (prm)-PASEF and dia-PASEF workflows were compared and we tested mixing patient intake sera for multiplexed target selection. RESULTS: No significant differences were observed in lowest detectable concentration, linearity, and slope coefficient when comparing prm-PASEF and dia-PASEF measurements of serial dilutions of patient sera. To improve assay development times, we tested multiplexing patient intake sera for target selection which resulted in the selection of identical clonotypic peptides for both simplex and multiplex dia-PASEF. Furthermore, assay development times improved up to 25× when measuring multiplexed samples for peptide selection compared to simplex. CONCLUSIONS: Dia-PASEF technology combined with automated data processing and multiplexed target selection facilitated the development of a faster MS-MRD workflow which benefits upscaling and is an important step towards the clinical implementation of MS-MRD.
650    _2
$a lidé $7 D006801
650    12
$a mnohočetný myelom $x diagnóza $x krev $7 D009101
650    12
$a reziduální nádor $x diagnóza $7 D018365
650    12
$a průběh práce $7 D057188
650    _2
$a rychlé screeningové testy $x metody $7 D057166
650    _2
$a individualizovaná medicína $x metody $7 D057285
650    _2
$a automatizace $7 D001331
655    _2
$a časopisecké články $7 D016428
700    1_
$a Armony, Gad $u Translational Metabolic Laboratory, Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands
700    1_
$a Noori, Somayya $u Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
700    1_
$a Gloerich, Jolein $u Translational Metabolic Laboratory, Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands
700    1_
$a Bonifay, Vincent $u Sebia, Lisses, France
700    1_
$a Caillon, Hélène $u Biochemistry Laboratory, Hospital of Nantes, Nantes, France
700    1_
$a Luider, Theo M $u Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
700    1_
$a Brehmer, Sven $u Bruker Daltonics GmbH, Bremen, Germany
700    1_
$a Pfennig, Lennard $u Bruker Daltonics GmbH, Bremen, Germany
700    1_
$a Srikumar, Tharan $u Bruker Ltd, Milton, CA, USA
700    1_
$a Trede, Dennis $u Bruker Daltonics GmbH, Bremen, Germany
700    1_
$a Kruppa, Gary $u Bruker S.R.O., Brno-City, Czech Republic
700    1_
$a Dejoie, Thomas $u Biochemistry Laboratory, Hospital of Nantes, Nantes, France
700    1_
$a van Duijn, Martijn M $u Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands $1 https://orcid.org/000000026654994X
700    1_
$a van Gool, Alain J $u Translational Metabolic Laboratory, Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands
700    1_
$a Jacobs, Joannes F M $u Laboratory of Medical Immunology, Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
700    1_
$a Wessels, Hans J C T $u Translational Metabolic Laboratory, Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands
773    0_
$w MED00010886 $t Clinical chemistry and laboratory medicine $x 1437-4331 $g Roč. 62, č. 12 (2024), s. 2507-2518
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38872409 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206104317 $b ABA008
999    __
$a ok $b bmc $g 2263272 $s 1239399
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 62 $c 12 $d 2507-2518 $e 20240617 $i 1437-4331 $m Clinical chemistry and laboratory medicine $n Clin Chem Lab Med $x MED00010886
LZP    __
$a Pubmed-20250121

Find record

Citation metrics

Archiving options